Skip to content

Clinical trials evaluating the effectiveness and safety of endoscopic surgical system-assisted laparoscopic radical prostate cancer resection

Clinical trials evaluating the effectiveness and safety of endoscopic surgical system-assisted laparoscopic radical prostate cancer resection

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057000
Enrollment
Unknown
Registered
2022-02-25
Start date
2022-02-22
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostatic cancer

Interventions

Experimental group:KD-SR-01 system
Control group:IS 3000

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosed as prostate cancer, TNM staging = T2N0M0, can be included in patients who have received neoadjuvant endocrine therapy before surgery; (2) The age is 18-75 years old, male (3) Ability to cooperate and complete follow-up visits and related examinations; (4) Voluntarily participate in this trial and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1)Patients with severe uncontrolled disease or acute infection. (2)The patients with cardiovascular and cerebrovascular diseases, blood system diseases and diabetes can not be controlled and can not reach the operation standard.(3)Those who have immune system disease and can't control, can't reach the operation standard. (4)Those who have not completed clinical trials involved in other research drugs or devices.

Design outcomes

Primary

MeasureTime frame
Success rate of operation;

Secondary

MeasureTime frame
Recovery of urine control;

Countries

China

Contacts

Public ContactJizhigang

Peking Union Medical College Hospital

jizhigang@pumch.cn13901170870

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026